Chemin Louis Dunant 15
M. Bernard Pécoul, fondateur et Directeur

Drugs for Neglected Diseases Initiative est un partenariat au développement à but non lucratif travaillant à la recherche et au développement des traitements nouveaux et améliorés pour les maladies négligées. Il s'agit particulièrement de la trypanosomiase humaine africaine, de la leishmaniose, de la maladie de Chagas et du paludisme

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases.

Founded in 2003 to address the needs of patients with the most neglected diseases, DNDi is a collaborative, patients’ needs-driven, not-for-profit drug R&D organization.


To improve the quality of life and the health of people suffering from neglected diseases by using an alternative model to develop drugs for these diseases and by ensuring equitable access to new and field-relevant health tools.

In this not-for-profit model, driven by the public sector, a variety of players collaborate to raise awareness of the need to research and develop drugs for those neglected diseases that fall outside the scope of market-driven R&D. They also build public responsibility and leadership in addressing the needs of these patients.


To develop new drugs or new formulations of existing drugs for people suffering from neglected diseases.
Acting in the public interest, DNDi bridges existing research and development (R&D) gaps in essential drugs
for these diseases by initiating and coordinating drug R&D projects in collaboration with the international
research community, the public sector, the pharmaceutical industry, and other relevant partners.


DNDi’s primary focus has been the development of drugs for the most neglected diseases, such as
human African trypanosomiasis (HAT, or sleeping sickness), visceral leishmaniasis (kala-azar), and Chagas disease,
while considering engagement in R&D projects for other neglected patients (e.g. malaria, paediatric HIV, filarial infections)
and development of diagnostics and/or vaccines to address unmet needs that others are unable or unwilling to address.

In pursuing these goals, DNDi enables R&D networks built on global collaborations. While harnessing existing support
capacities in countries where the diseases are endemic, DNDi contributes to strengthen capacities in a sustainable
manner, including through know-how and technology transfers in the field of drug R&D for neglected diseases.

In order to address the evolving needs of public health importance and maintain DNDi’s commitment to delivering
on the objectives of the current portfolio of diseases, a dynamic portfolio approach is adopted. This enables DNDi
to take on new disease areas with various operating models, while completing objectives in current diseases.


© Worldinz 2018